Outcomes With 5-Fluorouracil, Doxorubicin, and Streptozocin (FAS) and Subsequent Therapies in Patients With Well Differentiated Pancreatic Neuroendocrine Tumors (PanNETs)

被引：0
|
作者：
Lam, Michael [1 ]
Rogers, Jane [1 ]
Halperin, Daniel [1 ]
Dagohoy, Cecile [1 ]
Yao, James [1 ]
Dasari, Arvind [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
PANCREAS | 2019年 / 48卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：443 / 444
页数：2
相关论文
共 50 条
  • [31] The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.
    Raymond, Eric
    Kulke, Matthew H.
    Qin, Shukui
    Schenker, Michael
    Cubillo, Antonio
    Lou, Wenhui
    Tomasek, Jiri
    Thiis-Evensen, Espen
    Xu, Jianming
    Racz, Karoly
    Croitoru, Adina E.
    Khasraw, Mustafa
    Sedlackova, Eva
    Borbath, Ivan
    Ruff, Paul
    Oberstein, Paul Eliezer
    Ito, Tetsuhide
    Fernandez, Kathrine C.
    Rosbrook, Brad
    Fazio, Nicola
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [32] Angiogenic profiling in patients with advanced well-differentiated pancreatic neuroendocrine tumors treated with everolimus
    Cella, C. A.
    Spada, F.
    Galdy, S.
    Frezza, A. M.
    Catapano, M.
    Funicelli, L.
    Calleri, A.
    Zorzino, L.
    Mancuso, P.
    Radice, D.
    Fazio, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S449 - S449
  • [33] Elevated Levels of 5-HIAA and CgA in Patients With Pancreatic Neuroendocrine Tumors (PanNETs): Analyses From the CLARINET Study
    Phan, Alexandria T.
    Wolin, Edward M.
    Liyanage, Nilani
    Mirakhur, Beloo
    Lowenthal, Susan W. Pitman
    Vinik, Aaron I.
    Fisher, George A., Jr.
    Pavel, Marianne E.
    PANCREAS, 2018, 47 (03) : 350 - 351
  • [34] Pharmacotherapeutic Management of Well-Differentiated Neuroendocrine Tumors in Older Patients: Current Status and Potential Therapies
    Christiana Crook
    Ya-Han Zhang
    Daneng Li
    Drugs & Aging, 2022, 39 : 257 - 269
  • [35] Pharmacotherapeutic Management of Well-Differentiated Neuroendocrine Tumors in Older Patients: Current Status and Potential Therapies
    Crook, Christiana
    Zhang, Ya-Han
    Li, Daneng
    DRUGS & AGING, 2022, 39 (04) : 257 - 269
  • [36] Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives
    Marini, Francesca
    Giusti, Francesca
    Brandi, Maria Luisa
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2021, 16 (06) : 295 - 307
  • [37] Early-onset well differentiated pancreatic neuroendocrine tumors: Clinical presentation, pathologic features, and oncological outcomes
    Pulvirenti, Alessandra
    Hauser, Haley
    Le, Tiffany
    McIntyre, Caitlin A.
    Reidy, Diane Lauren
    Wei, Alice Chia-chi
    Raj, Nitya Prabhakar
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [38] Early Onset Well-Differentiated Pancreatic Neuroendocrine Tumors: Clinical Presentation, Pathologic Features, and Oncological Outcomes
    Pulvirenti, Alessandra
    Hauser, Haley
    Le, Tiffany
    McIntyre, Caitlin
    Reidy-Lagunes, Diane
    Wei, Alice
    Raj, Nitya
    PANCREAS, 2022, 51 (03) : E51 - E51
  • [39] The Efficacy and Safety of Sunitinib in Patients with Advanced Well Differentiated Pancreatic Neuroendocrine Tumors: Focus on Response Rate
    Raymond, E.
    Kulke, M. H.
    Qin, S.
    Yu, X.
    Schenker, M.
    Cubillo, A.
    Lou, W.
    Tomasek, J.
    This-Evensen, E.
    Fernandez, K.
    Rosbrook, B.
    Fazio, N.
    NEUROENDOCRINOLOGY, 2017, 105 : 225 - 225
  • [40] ISL-1 Expression is a Prognostic Marker in Patients With Well-Differentiated Pancreatic Neuroendocrine Tumors
    Assi, H.
    Hatoum, H.
    Maldonado-Vital, M.
    Fung, K. -M.
    PANCREAS, 2021, 50 (03) : 457 - 458
12345